Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival

Just over two years after spending more than $2 billion to acquire the drug, UCB announced that zilucoplan proved effective at treating the rare autoimmune disease myasthenia gravis in a large Phase III trial.